Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Русский
English
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ACAD
#1236
Acadia Pharmaceuticals Inc.
24.5
6
+1.24%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
+1.24%
Aylık değişim
-6.83%
6 aylık değişim
-7.08%
Yıllık değişim
+28.05%
Önceki kapanış
24.2
6
Open
24.5
6
Bid
Ask
Low
24.5
6
High
24.5
6
Hacim
140
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
ACAD
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Dividends per share
—
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
—
ACADIA Pharmaceuticals Inc
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Haberler
Acadia Pharmaceuticals: Undervalued Despite Robust Revenues From Approved Drugs (ACAD)
ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
Jefferies повысил целевую цену акций Acadia Pharmaceuticals
Jefferies raises Acadia Pharmaceuticals stock price target on guidance
Citizens повышает целевую цену Acadia Pharmaceuticals
Citizens raises Acadia Pharmaceuticals price target on growth outlook
ACADIA Pharmaceuticals Inc. (ACAD) Q4 2025 Earnings Call Transcript
ACADIA Pharmaceuticals Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:ACAD) 2026-02-25
Acadia Pharmaceuticals (ACAD) Q4 Earnings Top Estimates
ACADIA достигла $1 млрд выручки в 4 квартале 2025 года
ACADIA Q4 2025 slides: $1B revenue milestone as both drugs post double-digit growth
Acadia: рост дохода ожидается несмотря на снижение прибыли